Dr. Barry Karger has taught at Northeastern University for 53 years, and has spent 43 years as director of the Barnett Institute. But if you ask him about his retirement, he’ll tell you, “I’m not going to just go fishing.”
The Wolfgang Goetzinger-Amgen Memorial Scholar Award is in memory of Amgen’s well-respected and esteemed colleague, Wolfgang Goetzinger, an analytical chemist at Amgen’s Cambridge R&D facility and former post-doctoral fellow in the Barnett Institute at Northeastern University.
Professor Matthias Mann, Director in the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry in Munich, Germany, was the recipient the Inaugural Barry L. Karger Medal in Bioanalysis.
The prevailing view of research science is that professors and laboratory staff work on obscure challenges for which a lifetime might not be enough time to solve. Or that their projects might have limited application in the ‘real’ world. If that’s how you think, you haven’t met Dr. Barry Karger.
Dr. William Hancock, the Bradstreet Chair in Chemistry and Chemical Biology and an expert in protein drugs, has been invited to serve as a consultant as a consultant to the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA).
Northeastern professor Barry Karger, whose contributions to analytical chemistry helped enable the sequencing of the human genome, received the Arnold O. Beckman Medal and Award for Outstanding Scientific Achievements in the field of electrodriven separation techniques.
This year marks the 40th anniversary of the founding of Northeastern’s Barnett Institute of Chemical and Biological Analysis.
Northeastern University’s Barnett Institute of Chemical and Biological Analysis formally announced a technology alliance partnership with Thermo Fisher Scientific, a multibillion-dollar analytical instrumentation and product company, based in San Jose, Calif., with corporate offices in Waltham, MA.
Biologic drugs represent one of the most important and fastest growing areas in healthcare today, and especially as these biopharmaceuticals begin to come off patent and developers prepare for biosimilars to hit the market, there is a growing need for advanced analytics throughout the drug development process.